A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
← catalyst calendarSponsored by Korro Bio, Inc. (industry) · KRRO — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
42actual
Sites
5
Countries
Australia, New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was terminated for business decision reasons.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-13 | actual | When the study began enrolling |
| Primary completion | 2025-10-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-15 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alpha-1 Anti-trypsin Deficiency
- AATD
Intervention
- Drug: KRRO-110
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability
measured From Day 1 to Day 43 in the SAD and from Day 1 to Day 85 in the MAD
Permalink · KRRO's whole pipeline · Catalyst calendar · Every registered study · What changed